Safflower (Carthamus Tinctorius L.) Granules for Sepsis-associated Coagulopathy
Key facts
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 210 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- High-dose safflower granules
- Medium-dose safflower granules
- Placebo granules (one-tenth of medium-dose safflower)
- Record updated
- 27 October 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age >= 18 and <= 80 years at admission
- Meeting the Sepsis 3.0 diagnostic criteria, defined as infection-induced organ dysfunction with an increase in the Sequential Organ Failure Assessment (SOFA) score of >= 2 points from baseline
- Coagulopathy at admission, defined as fibrin degradation products (FDP) > 9.9 mg/L AND D-dimer > 3.3 mg/L
- Written informed consent obtained from the patient or legal representative
Who cannot take part
- Current treatment with anticoagulant or antiplatelet agents for underlying conditions before admission
- Requirement for any form of blood purification therapy or extracorporeal membrane oxygenation (due to mandatory anticoagulation)
- Known allergy or hypersensitivity to Carthamus tinctorius L. (safflower)
- Hematological disorders, autoimmune diseases, or advanced malignancy
- Confirmed venous thromboembolism
- Conditions with potential bleeding risk, including severe traumatic brain injury, cerebral aneurysm, arteriovenous malformation, bronchiectasis, or gastrointestinal ulcer; or within 24 hours of severe trauma or major surgery
- Pre-existing chronic organ failure: cardiac failure (long-term left ventricular assist device or inotropic agents); hepatic failure (Child-Pugh class C); chronic respiratory failure (long-term home oxygen or non-invasive ventilation); chronic renal failure (glomerular filtration rate < 30 mL/min/1.73m2, or regular hemodialysis)
- Pregnant or lactating women
- Life expectancy < 48 hours
- Participation in other interventional clinical trials within the study period
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening condition in which infection triggers widespread inflammation and blood clotting abnormalities. Many patients with sepsis develop coagulopathy (impaired blood clotting), which contributes to organ damage and death. Safflower (Carthamus tinctorius L.) is a traditional Chinese medicine herb with documented anticoagulant, anti-platelet, and blood vessel-protective properties. This randomized, double-blind, placebo-controlled trial will enroll 210 adult patients with sepsis-associated coagulopathy at Ruijin Hospital. Participants will be randomly assigned to one of three groups: high-dose safflower granules (equivalent to 9 g of raw herb daily), medium-dose safflower granules (equivalent to 6 g of raw herb daily), matching placebo (equivalent to 0.6 g of raw herb daily for blinding). The granules are dissolved in 50 mL of warm water and given through a nasogastric tube once daily for 7 days, in addition to standard sepsis treatment. The primary outcome is the improvement in the SOFA score (a measure of organ function) at 14 days. Secondary outcomes include DIC scores, coagulation tests, endothelial injury and platelet markers, inflammatory markers, 28-day mortality, length of ICU and hospital stay, and adverse events. The study is funded by Ruijin Hospital as an investigator-initiated trial.
The 3 groups in the trial
- High-Dose SafflowerTreatment being tested
Safflower (Carthamus tinctorius L.) granules equivalent to 9 g of raw herb, dissolved in 50 mL of warm water and given via nasogastric tube once daily for 7 consecutive days or until clinical stabilization, plus standard-of-care sepsis treatment.
Treatment: High-dose safflower granules
- Medium-Dose SafflowerTreatment being tested
Safflower (Carthamus tinctorius L.) granules equivalent to 6 g of raw herb, dissolved in 50 mL of warm water and given via nasogastric tube once daily for 7 consecutive days or until clinical stabilization, plus standard-of-care sepsis treatment.
Treatment: Medium-dose safflower granules
- Placebo granules (one-tenth of medium-dose safflower)Placebo, for comparison
Safflower (Carthamus tinctorius L.) granules at one-tenth of the medium dose (equivalent to 0.6 g of raw herb), dissolved in 50 mL of warm water and given via nasogastric tube once daily, same duration as the safflower groups, plus standard-of-care sepsis treatment. The one-tenth dose serves blinding by matching the appearance and odor of the study granules.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Safflower (Carthamus Tinctorius L.) Granules in Patients With Sepsis-associated Coagulopathy: a Randomized, Double-blind, Controlled, Three-arm Trial
- Criteria questions
- Built from NCT07897006, who can take part
- Record updated
- 27 October 2026